Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States
The REVEAL trial—an ongoing, prospective, observational study of US patients with polycythemia vera—published patient-reported outcomes from the beginning of the study, showing that patients with PV experience high symptom burden and impairments in their daily activities, work, and overall quality of life.
Clinical Lymphoma, Myeloma & Leukemia
In The News
Oncology Nurse Advisor
Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
American Journal of Managed Care
New Guideline Released on Managing Complications in Polycythemia Vera
Oncology Nurse Advisor
Case Study: Myelofibrosis Diagnosis and Early Intervention
In The Literature
Blood (ASH Abstract)
A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination With Ruxolitinib in Patients with Myelofibrosis
Blood (ASH Abstract)
Independent Association of Male Sex With Presentation and Clinical Outcomes in Myeloproliferative Neoplasms
American Journal of Hematology
Myeloproliferative Neoplasms in the Young: Mayo Clinic Experience With 361 Patients Age 40 Years or Younger
European Journal of Haematology